Bionet Corp

Chart & Performance

D1W1MN

P/E

63.09

P/S

2.62

EPS

1.10

Div Yield, %

2.05%

Shrs. gr., 5y

-55.49%

Rev. gr., 5y

8.92%

Revenues

1.24b

+1.19%

Net income

51m

-38.56%

CFO

148m

-16.12%

Dividend

Oct 01, 20260.87237 TWD/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Established in 1989 and headquartered in Taipei City, Taiwan, BIONET Corp. is a global leader in umbilical cord blood preservation, serving clients across Taiwan and internationally. The company provides a comprehensive suite of stem cell banking services, encompassing the storage of general stem cells, mesenchymal stem cells, dental stem cells, adipose stem cells, and peripheral blood stem cells combined with immune cells. Beyond its core stem cell preservation, BIONET also conducts genetic testing services. Its product offerings further extend to anti-aging solutions leveraging stem cell technology, alongside its unique ANIKINE series. Additionally, the company is a pioneer in offering Exosome, an innovative cell-free therapeutic approach.

URL

https://www.bionetcorp.com/

IPO date

Sep 17, 2004

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title TWD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title TWD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT